NCT03975647 2025-12-10A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerSeagen Inc.Phase 3 Active not recruiting466 enrolled 17 charts
NCT04419181 2025-10-14Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast CancerUniversity of RochesterPhase 2 Withdrawn